(Reuters) -The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and ...

The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower ...

Numerous recalls have been issued this year due to the potential for damaged products and undeclared food allergens.

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month ...

Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March ...

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...

() -​Rhythm Pharmaceuticals ‌said on Friday ‌the U. Food and ⁠Drug ‌Administration has extended the ‍review period for ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...